tbuckley/cabot-search huggingface dataset:
Activation Of TAK1 By MYD88 L265P Drives Malignant B Cell Growth In Non-Hodgkin Lymphomas
Authors: Stephen M Ansell, Lucy S. Hodge, Frank Secreto, Michelle Manske, Esteban Braggio, TAmmy Price-Troska, Steven Ziesmer, Ying Li, Sarah Johnson, Steven Hart, Jean-Pierre Kocher, George Vasmatzis, Asher Chanan-Khan, Morie Abraham Gertz, Rafael Fonseca, Ahmet Dogan, James R Cerhan, Anne J. Novak
Journal: Blood (2013)
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602.
Authors: TAKASHI ONDA, Hiroyuki Yoshikawa, Taro Shibata, Kenichi Nakamura, Toyomi Satoh, Toshiaki Saito, Takahiro Kasamatsu, Toru Nakanishi, Takayoshi Nogawa, Motoaki Saitou, Kimio Ushijima, Hiroaki Kobayashi, Tadao Takano, Kei Kawana, Harushige Yokota, Masashi Takano, Nobuhiro Takeshima, Nobuo Yaegashi, Ikuo Konishi, Toshiharu Kamura
Journal: Journal of Clinical Oncology (2014)

5508 Background: We conducted a phase III trial comparing upfront primary debulking surgery (PDS) and NAC for stage III/IV ovarian, tubal and peritoneal cancers (JCOG0602). Two preceding studies, EORTC55971 and CHORUS, successfully demonstrated non-inferior survival of patients treated with NAC. However, invasiveness of treatment (Tx) has not yet fully been analyzed. To prove efficacy of NAC compared to standard Tx, it is necessary to demonstrate apparently reduced invasiveness of Tx. (UMIN-CTR: UMIN000000523). Methods: JCOG0602 is now on-going and the primary analysis of OS is planned in 2016. Patients were randomized to standard arm (PDS followed by 8 cycles of paclitaxel and carboplatin, i.e. TC regimen) and NAC arm (4 cycles of TC, interval debulking surgery [IDS], 4 cycles of TC). In standard arm, IDS was optional for patients who underwent suboptimal or incomplete PDS. Surgical invasiveness and incidence of adverse events related to Tx were compared between two arms. Results: From Nov 2006 to Oct 2011, 301 patients (149 standard arm and 152 NAC arm) were randomized. In standard arm 147/149 underwent PDS and 46 of them and 132/152 in NAC arm underwent IDS. Though pelvic and paraaortic lymphadenectomy (PLA/PALA) were more frequently performed in NAC arm (P<0.01), frequency of bowel or organ resection was lower in NAC arm (P<0.01). In a comparison between PDS in standard arm and IDS in NAC arm, blood/ascites loss (<0.01), albumin transfusion (<0.01), and G3/4 adverse events after surgery in total were fewer in IDS. Conclusions: Tx with NAC is less invasive than standard Tx. When non-inferior survival will be confirmed in this trial and new staging system is established, Tx with NAC can become a new standard Tx for advanced ovarian cancer. Clinical trial information: UMIN000000523. Standard arm (N=149) NAC arm (N=152) p value PLA 57 94 <0.01 PALA 27 65 <0.01 Bowel or organ resection 66 39 <0.01 Treatment-related death 2 1 0.62 Comparison of surgery PDS (N=147) IDS (N=132) Blood/ascites loss (median) 3,235 ml 795 ml <0.01 Red cell transfusion 75 72 0.63 Alb transfusion 86 35 <0.01 G3/4 adverse events During surgery 1 16 1.00 After surgery 22 6 <0.01
Bariatric Surgery for Patients With Type 2 Diabetes
Authors: Azeem Majeed
Journal: JAMA Surgery (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Thoracic duct lesions in thyroid surgery: An update on diagnosis, treatment and prevention based on a cohort study
Authors: Andrea Polistena, Jacopo Vannucci, Massimo Monacelli, Roberta Lucchini, Alessandro Sanguinetti, Stefano Avenia, Stefano Santoprete, Roberta Triola, Roberto Cirocchi, Francesco Puma, Nicola Avenia
Journal: International Journal of Surgery (2015)
Adoptive immunotherapy and therapeutic concurrent chemoradiation have synergistic antitumor effects in a mouse model of squamous cell carcinoma
Authors: Jeffrey Moyer, Ji Li, Alfred Chang
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

4622 

Concurrent chemotherapy and fractionated radiation are being increasingly used as the initial treatment for many patients with squamous cell carcinomas of the head and neck (SCCHN) in an effort to preserve function at the primary site as well as to possibly improve survival. Despite this treatment approach, many patients die from locoregional and distant disease. Adoptive immunotherapy with tumor-draining lymphocytes has been used by some investigators to try and improve survival in patients at high risk for recurrence or regional and distant metastases. In an effort to improve outcomes in this patient population, we undertook experiments to determine the feasibility of adoptive transfer of tumor-draining lymphocytes in mice treated with chemotherapy and fractionated radiation.    Mice with 7-day subcutaneous SCCVII tumors were treated with 2 days of systemic cisplatin (4 mg/kg) and 5-fluorouracil (50 mg/kg) and 5 days of fractionated radiation to the flank tumor site (3 Gy/day; 15 Gy total). Tumor-draining lymph nodes (TDLN) from untreated mice with 9-day SCCVII tumors were harvested and activated for two days with anti-CD3 and anti-CD28 mAbs and subsequently expanded with IL-2 (60 IU/mL) for 3 more days. Mice were given a single intravenous injection of TDLN (30 x 106) three days after the completion of chemoradiation treatment (Day 14). Mice treated with chemoradiation or chemoradiation and TDLN had significantly slower tumor growth and better survival when compared to no treatment or TDLN alone-treated groups (p < 0.05). In addition, 2/20 (10%) of chemoradiation-treated animals and 3/20 (15%) of TDLN/chemoradiation-treated animals had a complete tumor response as compared to 0/20 (0%) in both untreated and TDLN alone-treated animals. Importantly, TDLN/chemoradiation-treated mice with a complete tumor response were completely resistant to multiple, repeat tumor challenges while chemoradiation-treated mice developed tumor with the initial rechallenge of relevant tumor. Consistent with these findings, splenocytes from TDLN/chemoradiation-treated mice had elevated levels of baseline interferon-gamma that was further increased by stimulation with relevant tumor when compared to controls.    These experiments suggest a systemic antitumor effect of adoptive immunotherapy with tumor-draining lymphocytes and chemoradiation and support a potential role for this treatment approach in patients with SCCHN undergoing standard chemoradiation protocols.
LP17 : Novel approach for the prevention of recurrent hepatitis C in liver transplant recipients: Preliminary results from ongoing phase III trial with civacir®
Authors: N. Terrault, R. Shrestha, S.K. Satapathy, J.G. O’Leary, J. Campsen, J. Rosenau, J. Spivey, L.W. Teperman, G. Therapondos, E.C. Verna, J.M. Vierling, T.D. Schiano, L. Sher, H. Khallafi, D. Victor, K.R. Bhamidimarri, F.D. Gordon, S. Hanish, L.M. Kulik, G. Lake-Bakaar, D. Maluf, M. Porayko, S.L Bramer, G. Osgood, S. Chavan, N. Daelken
Journal: Journal of Hepatology (2015)
Ischemia, Revascularization, and Perioperative Troponin Elevation After Vascular Surgery**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology
Authors: Debabrata Mukherjee, Kim A. Eagle
Journal: Journal of the American College of Cardiology (2004)
Human leucocyte antigen (HLA) A2 phenotype incidence in patients with advanced ovarian cancer as negative clinical prognostic factor
Authors: G. V. Masucci, Z. Gamzatova, L. Villabona, L. Dahlgren, T. Dalianis, E. Åvall-Lundqvist, K. Bergfeldt
Journal: Journal of Clinical Oncology (2005)

5096 Background: Major histocompatibility complex (class I-II) antigens are mandatory for the immune response and genetic imbalance may be linked to tumour escape. We characterized a cluster of ovarian cancer patients with high incidence of HLA-A2 phenotype. The prevalence of A2 allele found in Scandinavia decreases with latitude in Europe and correlates to the decrease of ovarian cancer mortality. To find a prognostic relevance, we correlate the HLA-A2 phenotype to well defined clinical parameters. Methods: All patients with ovarian cancer, admitted at our department during 1995 were recorded in a database by age, histology, stage, surgery and treatment. Since the majority of the cases were not alive, HLA-A2 expression was determined by PCR/sequence-specific oligonucleotide hybridisation using DNA extracted from paraffin imbedded tissue specimens. Purified tissue was disrupted at 55°C in 10% SDS, proteinase K buffer twice. Amount and purity of DNA was measured by Nano-Drop technology. Results: 97 patients with ovarian cancer entered the database, median age 65 years (36–87). Forty-six percent were seropapillary, 28% endometrial, 6% mucinous and 20% other tumours. Merged by stage, 32 were I-II and 65 III-IV. At 5 years, 70% stage I-II and 20% stage III-IV patients were alive. So far, 24 out of 97 patients are characterised for HLA-A2 phenotype. Fifteen were HLA-A2 positive (66%) and 10 of 15 with stage III-IV, were 90% seropapillary tumours. At five years, none of A2 positive, but 50% A2 negative patients were alive. Conclusions: The overrepresentation of HLA-A2 phenotype is a possible negative clinical parameter for survival for ovarian cancer patients with stage III-IV and seropapillary type. A stronger statistical power will be reached after analysis of all cases. No significant financial relationships to disclose.
Can Stereotactic Body Radiotherapy Effectively Treat Hepatocellular Carcinoma?
Authors: Aisling Barry, Jennifer J. Knox, Alice C. Wei, Laura A. Dawson
Journal: Journal of Clinical Oncology (2015)

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.A 78-year-old woman with a past medical history of hepatitis C virus (HCV) presented on routine examination to her family doctor with abnormal liver function tests. She was referred for liver ultrasound, which detected a liver mass. Multiphasic magnetic resonance imaging (MRI) diagnosed liver cirrhosis and a segment 7/8 lesion measuring 4 cm, suspicious for a hepatocellular carcinoma (HCC), without evidence of portal hypertension. Child-Pugh (CP) score (ranging from 5 to 15) is a clinically relevant measure of synthetic liver function, based on international normalized ratio and albumin and bilirubin levels, as well as presence or absence of ascites and encephalopathy. A score of A5 or 6 is associated with better postoperative survival compared with CP B7 to 9 or CP C10 to 15, in which surgery is contraindicated. Her CP score was A6, based on a low albumin of 34 g/L. Platelets were slightly depressed at 121,000 μL, and alpha-fetoprotein level was 89 μg/L. She had not received treatment of her HCV because of her age and low viral load. She does not drink alcohol. Clinically the patient had an Eastern Cooperative Oncology Group performance status (PS) of 1, no stigmata of chronic liver disease, and no ascites or encephalopathy or other associated clinical symptoms. An HCC multidisciplinary cancer conference recommended surgical resection. The patient was taken to the operating room for a planned liver nonanatomic wedge resection. At the time of laparotomy, extensive cirrhosis was found and resection was abandoned because of the high risk of liver failure. A biopsy was not obtained, as the tumor had classic arterial enhancement and washout on venous and delayed-phase computed tomography (CT) imaging, which is diagnostic for HCC. After laparotomy, the patient developed liver insufficiency manifested by new ascites and peripheral edema, treated with diuretics, a low-salt diet, and fluid restriction. She was discharged home after a week and referred for a radiation oncology opinion. Three months after laparotomy, her liver function had recovered, with resolution of her ascites and PS of 2. It was decided to proceed with nonsurgical local therapy to the liver mass with curative intent.
Rates and risks for late referral to hospice in patients with primary malignant brain tumors
Authors: Eli L. Diamond, David Russell, Maria Kryza-Lacombe, Kathryn H. Bowles, Allison J. Applebaum, Jeanne Dennis, Lisa M. DeAngelis, Holly G. Prigerson
Journal: Neuro-Oncology (2015)

Primary malignant brain tumors (PMBTs) are devastating malignancies with poor prognosis. Optimizing psychosocial and supportive care is critical, especially in the later stages of disease. This retrospective cohort study compared early versus late hospice enrollment of PMBT patients admitted to the home hospice program of a large urban, not-for-profit home health care agency between 2009 and 2013. Of 160 patients with PMBT followed to death in hospice care, 32 (22.5%) were enrolled within 7 days of death. When compared with patients referred to hospice more than 7 days before death, a greater proportion of those with late referral were bedbound at admission (97.2% vs 61.3%; OR=21.85; 95% CI, 3.42–919.20; P < .001), aphasic (61.1% vs 20.2%; OR = 6.13; 95% CI, 2.59–15.02; P < .001), unresponsive (38.9% vs 4%; OR = 14.76,;95% CI, 4.47–57.98; P < .001), or dyspneic (27.8% vs 9.7%; OR = 21.85; 95% CI, 3.42–10.12; P = .011). In multivariable analysis, male patients who were receiving Medicaid or charitable care and were without a health care proxy were more likely to enroll in hospice within 1 week of death. Late hospice referral in PMBT is common. PMBT patients enrolled late in hospice are severely neurologically debilitated at the time hospice is initiated and therefore may not derive optimal benefit from multidisciplinary hospice care. Men, patients with lower socioeconomic status, and those without a health care proxy may be at risk for late hospice care and may benefit from proactive discussion about end-of-life care in PMBT, but prospective studies are needed.
Transcutaneous pCO2 monitoring as an alternative to arterial line sampling: A cost-effectiveness analysis
Authors: James van Oppen, Milind Sovani
Journal: European Respiratory Journal (2014)

Objective:  To evaluate the clinical role and cost effectiveness of transcutaneous pCO 2  monitoring compared to arterial line sampling during the acute phase of non-invasive ventilation therapy.   Subjects and methods:  Ten inpatients were recruited at the Medical High Dependency Unit, Queen9s Medical Centre, Nottingham. All were receiving NIV for acute hypercapnic respiratory failure and had arterial lines placed. During 48 hours of concurrent monitoring with Radiometer transcutaneous TOSCA TCM4 and arterial ABL90 blood gas analysers the staff-time, consumables and proportionate hardware costs were determined and compared. Patient-reported pain scores were analysed using the Wilcoxon signed rank test, and pCO 2  data from each monitor were plotted as time trends.   Results:  Over 48-hour periods, a mean 16 samples were taken from each patient. Transcutaneous monitoring was less painful and produced pCO 2  time trends concordant to arterial sampling. Staff-time costs to establish monitoring and obtain data were £0.13 (transcutaneous) and £1.83 (arterial) per sample. Consumable and disposal costs were £3.35 (transcutaneous) and £3.74 (arterial) per sample taken. Initial device purchase and estimated device-life readings corresponded to hardware costs of £0.78 (transcutaneous) and £1.37 (arterial) per sample.   Conclusions:  Transcutaneous pCO 2  monitoring provided reliable time trends, improved patient experience and was cost effective (£4.27 vs £6.94) compared to arterial lines. For a unit that provides acute NIV for 148 patients each year, monitoring transcutaneous rather than arterial pCO 2  would represent an annual saving of £6325.
Public Health England's report on sugar reduction
Authors: M. Rayner, P. Scarborough, A. Briggs
Journal: BMJ (2015)

Its list of actions is good; now we need priorities

Public Health England (PHE) has published its long awaited report on the evidence for sugar reduction.1 It sets out eight key levers that the government could use when formulating a programme to reduce the population’s intake of free sugars (all sugars added to foods plus those naturally present in fruit juices, syrups, and honey).

There is much to applaud. PHE is often criticised for not being bold enough in its recommendations to government, taking a cautious approach to its interpretation of the evidence and what it should mean to policy makers. However, at least four of the eight levers may need some form of legislation, and the range of suggested interventions goes beyond simply nudging individuals through health education (box). The breadth of the review is a strength: diet is complex and there is no silver bullet. No single policy will reduce sugar intake, and reducing sugar consumption in itself will not solve the obesity epidemic. A multifaceted approach is needed.

However, the breadth of the report is also its biggest problem. The mixed methodological approach is clumsy, ranging from systematic reviews of the evidence underlying fiscal interventions and reducing opportunities for marketing, through to a specially commissioned analysis of Kantar Worldpanel data to assess the effectiveness of reducing price promotions. …
CLASS clarification: reaffirms the medical importance of the analyses and results
Authors: G Steven Geis
Journal: BMJ (2003)

From BMJ USA 2002;September:522 

We appreciate the opportunity to correct the inaccuracies in the article by Juni et al,1 which appear to be based on an incomplete understanding of the CLASS design, data, and statistical issues. Contrary to the editorial's assertions, there were no post hoc changes in the study design or the outcome definitions. The CLASS authors reviewed all the data and decided the 6-month analyses were most appropriate for initial publication,2 while the FDA chose 9-month data as most appropriate for a recent label change.3 Despite differing medical judgment for the time interval that best reflected the data, and contrary to the BMJ editorial allegations, the conclusions were similar.

CLASS was a single study with the objective of comparing the rate of ulcer complications with celecoxib versus traditional NSAIDs. The need for two protocols was prespecified to ensure blinding of study medications. One protocol included celecoxib 400 mg BID and ibuprofen 800 mg TID; the other included celecoxib 400 mg BID and diclofenac 75 mg BID. Aside from this difference and the inclusion of quality of life measures in one protocol, the protocols were …
Overnight oximetry as a screening tool for diagnosing obstructive sleep apnea in high altitude residents
Authors: B.N.B. Mahaveera Prasad, C.A. Tukaram
Journal: European Respiratory Journal (2011)

Aim:  To determine the value of overnight nocturnal oximetry in strongly suspected cases of obstructive sleep apnea (OSA) among residents of high altitude.   Methods:  This study is a retrospective analysis of prior overnight oximetry data of permanent residents staying at altitudes between 7000 to 8000 feet above the sea level who had a high pretest probability of OSA. The cases in this study were subsequently confirmed to have OSA by overnight sleep study (polysomnography). To determine the mean daytime and nocturnal oxygen saturation values for comparision with the study group, matched healthy non smokers residing in the area were studied by daytime and nocturnal oximetry.   Results:  There were 12 males and 9 females in the study who had confirmed OSA.They were in the age group between 36 to 48 years. All had severe OSA.Nocturnal oximetry in these cases revealed more than 15 events of oxygen desaturation per hour of sleep with oxygen saturation falling more than 10 percent below pre-sleep awake baseline values. The awake oxygen saturation of all these cases were normal and were matching with mean value of 92 percent observed among 20 controls.The nocturnal oxygen desaturation among control group was less than 4 percent of awake values and events of desaturation were less than 5 times per hour of sleep.   Conclusion:  Overnight oximetry is a useful screening tool in cases of OSA residing at high altitude areas.It can be used to confirm diagnosis of OSA in cases with a high pretest probability.